DAY 0
(continued)
(continued)
Liposomal Amphotericin B treatment
initiated for mucormycosis*,**
initiated for mucormycosis*,**
Ahmad had facial paralysis, swelling around his right
eye, and his right eyelid had drooped. He had little to
no bilateral movement in his right eye and his right
soft palate showed blackish discolouration. He had
anxiety, tachypnoea with normal oxygen saturation and
was haemodynamically stable and alert.
eye, and his right eyelid had drooped. He had little to
no bilateral movement in his right eye and his right
soft palate showed blackish discolouration. He had
anxiety, tachypnoea with normal oxygen saturation and
was haemodynamically stable and alert.
Rhino-orbito-cerebral (ROC) mucormycosis
was highly suspected based on the results of
an MRI scan.*
was highly suspected based on the results of
an MRI scan.*
Ahmad was immediately started on treatment
with Liposomal Amphotericin B (5 mg/kg/day
over 6 hours) but had no initial response.†
with Liposomal Amphotericin B (5 mg/kg/day
over 6 hours) but had no initial response.†
*Liposomal Amphotericin B is indicated in the UK for the empirical treatment of presumed fungal infections in
febrile neutropenic patients, where the fever has failed to respond to broad-spectrum antibiotics and appropriate
investigations have failed to define a bacterial or viral cause.6 In this case, the responsible physician made the
decision to initiate therapy with strong clinical suspicion of mucormycosis due to the potential for significant impact on
outcome. This case is intended for educational and illustrative purposes only, and does not constitute a recommendation
for clinical practice.
febrile neutropenic patients, where the fever has failed to respond to broad-spectrum antibiotics and appropriate
investigations have failed to define a bacterial or viral cause.6 In this case, the responsible physician made the
decision to initiate therapy with strong clinical suspicion of mucormycosis due to the potential for significant impact on
outcome. This case is intended for educational and illustrative purposes only, and does not constitute a recommendation
for clinical practice.
**Please refer to the Summary of Product Characteristics of your chosen treatment prior to prescribing.
†Administration of a test dose is advisable before a new course of Liposomal Amphotericin B treatment.6
†Administration of a test dose is advisable before a new course of Liposomal Amphotericin B treatment.6
Why Liposomal Amphotericin B
Decision point
Results
